Nakamura Asako, Ashizuka Yuki, Kobayashi Takayuki, Ueda Saori, Shigemura Hiroaki, Biwa Miki, Ichihara Sachiko, Tanaka Yoshito, Katsuki Susumu
Department of Health Science, Fukuoka Institute of Health and Environmental Sciences, Japan.
Department of Management, Fukuoka Institute of Health and Environmental Sciences, Japan.
Jpn J Infect Dis. 2022 Nov 22;75(6):627-630. doi: 10.7883/yoken.JJID.2022.079. Epub 2022 Jul 29.
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first confirmed in Japan on January 15, 2020. The Fukuoka Institute of Health and Environmental Sciences conducted testing using polymerase chain reaction (PCR) for SARS-CoV-2 from January 31 to March 4, 2020. Samples (n = 119) were collected from 81 patients suspected of having SARS-CoV-2 infection, presenting with fever, cough, fatigue, pneumonia, and other symptoms; all the samples tested during that period were negative. To identify the pathogens responsible for these symptoms, we conducted multiplex PCR. Respiratory viruses, human metapneumovirus (hMPV) was detected in 10 patients (12%), human rhinovirus (HRV) in 3 patients (4%), and influenza B virus in 1 patient (1%). In addition, the patients who had the viruses were significantly older than those who did not. Infections with hMPV and HRV have been associated with a risk of severe illness and death among older adults. Therefore, differentiating SARS-CoV-2 from other respiratory viruses, such as hMPV and HRV, is necessary to prevent and control the spread of infection, especially in older adults.
2019冠状病毒病由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，于2020年1月15日在日本首次确诊。福冈健康与环境科学研究所于2020年1月31日至3月4日使用聚合酶链反应（PCR）对SARS-CoV-2进行检测。从81名疑似感染SARS-CoV-2、出现发热、咳嗽、疲劳、肺炎及其他症状的患者中采集了样本（n = 119）；在此期间检测的所有样本均为阴性。为了确定导致这些症状的病原体，我们进行了多重PCR。在呼吸道病毒检测中，10名患者（12%）检测出人偏肺病毒（hMPV），3名患者（4%）检测出人类 rhinovirus（HRV），1名患者（1%）检测出乙型流感病毒。此外，感染病毒的患者年龄显著高于未感染病毒的患者。hMPV和HRV感染与老年人患重病和死亡的风险有关。因此，区分SARS-CoV-2与其他呼吸道病毒，如hMPV和HRV，对于预防和控制感染传播至关重要，尤其是在老年人中。
